These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 369589)
1. Size of cancer clinical trials and stopping rules. Pocock SJ Br J Cancer; 1978 Dec; 38(6):757-66. PubMed ID: 369589 [TBL] [Abstract][Full Text] [Related]
2. Interim analyses of survival data in cancer clinical trials. Skovlund E Acta Oncol; 1998; 37(7-8):645-50. PubMed ID: 10050981 [TBL] [Abstract][Full Text] [Related]
3. Interim analyses for randomized clinical trials: the group sequential approach. Pocock SJ Biometrics; 1982 Mar; 38(1):153-62. PubMed ID: 7082757 [TBL] [Abstract][Full Text] [Related]
4. Sequential clinical trials in cancer research. George SL Cancer Treat Rep; 1980; 64(2-3):393-7. PubMed ID: 7407775 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II designs in cancer clinical trials: current status and future directions. Lee JJ; Feng L J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154 [TBL] [Abstract][Full Text] [Related]
7. Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. Stallard N; Rosenberger WF Stat Med; 2002 Feb; 21(4):467-80. PubMed ID: 11836730 [TBL] [Abstract][Full Text] [Related]
8. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit. Lachin JM Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716 [TBL] [Abstract][Full Text] [Related]
9. Interim analyses and stopping rules in cancer clinical trials. Whitehead J Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370 [TBL] [Abstract][Full Text] [Related]
10. Interim analyses, stopping rules and data monitoring in clinical trials in Europe. Buyse M Stat Med; 1993 Mar; 12(5-6):509-20. PubMed ID: 8493429 [TBL] [Abstract][Full Text] [Related]
11. Flexible implementations of group sequential stopping rules using constrained boundaries. Burington BE; Emerson SS Biometrics; 2003 Dec; 59(4):770-7. PubMed ID: 14969454 [TBL] [Abstract][Full Text] [Related]
12. Statistical problems in the reporting of clinical trials. A survey of three medical journals. Pocock SJ; Hughes MD; Lee RJ N Engl J Med; 1987 Aug; 317(7):426-32. PubMed ID: 3614286 [TBL] [Abstract][Full Text] [Related]
13. Application of a new multinomial phase II stopping rule using response and early progression. Dent S; Zee B; Dancey J; Hanauske A; Wanders J; Eisenhauer E J Clin Oncol; 2001 Feb; 19(3):785-91. PubMed ID: 11157032 [TBL] [Abstract][Full Text] [Related]
14. Stopping rules and estimation problems in clinical trials. Hughes MD; Pocock SJ Stat Med; 1988 Dec; 7(12):1231-42. PubMed ID: 3231947 [TBL] [Abstract][Full Text] [Related]
16. Frequentist evaluation of group sequential clinical trial designs. Emerson SS; Kittelson JM; Gillen DL Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678 [TBL] [Abstract][Full Text] [Related]
17. Repeated confidence intervals for group sequential clinical trials. Jennison C; Turnbull BW Control Clin Trials; 1984 Mar; 5(1):33-45. PubMed ID: 6713906 [TBL] [Abstract][Full Text] [Related]
18. Sequential stopping rules in clinical trials. McPherson K Stat Med; 1990 Jun; 9(6):595-600. PubMed ID: 2218163 [TBL] [Abstract][Full Text] [Related]
19. Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Goldman AI Control Clin Trials; 1987 Dec; 8(4):327-37. PubMed ID: 3327653 [TBL] [Abstract][Full Text] [Related]
20. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility. Walter SD; Han H; Briel M; Guyatt GH Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]